On May 29, analysts at Stifel raised their price target for Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) from $78 to $94 while maintaining their Buy rating for the company’s shares. The change follows a thorough evaluation of the company’s prospects, particularly in relation to its obesity medication, setmelanotide, and its upcoming products.
To understand Rhythm Pharmaceuticals’ future, the Stifel team examined three key areas. They began by estimating the magnitude of the hypothalamic obesity (HO) market and concluded that it might be as large as previously expected. They also examined the anticipated rates of use of setmelanotide in treating HO and found that the medication might either meet or surpass the already high expectations. In addition, they examined the possibility of successful phase 2 studies for the company’s pipeline medications, RM-718 and bivamelagon.
Following their examination, the analysts seemed more optimistic about the company’s future. They cited the expected introduction of the HO therapy in 2026 as well as a number of impending clinical milestones in 2025 as encouraging drivers for the stock.
Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds
